October 20, 2025 02:30 ET | Source: IO Biotech Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression…
October 19, 2025 08:00 ET | Source: Replimune, Inc. WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc.…